|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The FUS gene at 16p11 fuses with DDIT3 and ATF1 as the result of translocations with chromosome band 12q13 in myxoid liposarcoma and angiomatoid fibrous histiocytoma, respectively, and with ERG as the result of a t(16;21)(p11;q22) in acute myeloid leukemia.
|
12915480 |
2003 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our observations suggest that expression of FUS-CHOP may be the initiating event in myxoid liposarcoma pathogenesis, and that MPCs may constitute one cell type from which these tumors originate.
|
16849546 |
2006 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe here a case of myxoid liposarcoma containing two novel FUS/CHOP chimeric transcripts and with the breakpoint occurring in intron 14 of FUS.
|
11162437 |
2000 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Described here is the use of detecting TLS/FUS-CHOP fusion transcripts to confirm the diagnosis of a myxoid liposarcoma by nested reverse transcription-polymerase chain reaction assay using archival formalin-fixed, paraffin-embedded tissues of a young man with a benign-looking myxoid tumor on his upper extremity, which is often misdiagnosed clinically or histopathologically as a benign tumor.
|
12930346 |
2003 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downstream of the gene for the liposarcoma-associated fusion oncoprotein 54 (DOL54) is a target gene of the myxoid liposarcoma and round cell liposarcoma (M-LPS/RC-LPS) oncogene, TLS/FUS-CHOP.
|
12366807 |
2002 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, endogenous mesenchymal stem cells (MSCs) expressing TLS:CHOP developed into MRCLS in vivo.
|
22293175 |
2012 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since the total number of patients is still limited, further studies are required to verify a putative association of type I FUS/DDIT3-fusion transcripts with a prognosis of MRCL.
|
17647282 |
2007 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21).
|
7566973 |
1995 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor.
|
21403840 |
2011 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS-DDIT3 dependency and biological function of the IGF-IR/PI3K/Akt signaling cascade were analyzed using a HT1080 fibrosarcoma-based myxoid liposarcoma tumor model and multiple tumor-derived myxoid liposarcoma cell lines.
|
28637688 |
2017 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human myxoid liposarcoma contains a characteristic t(12;16) chromosomal translocation that results in fusion of the N-terminal domain of the translocated in liposarcoma (TLS) protein to the C/EBP homologous protein (CHOP).
|
12168660 |
2002 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myxoid/round-cell liposarcoma (MLS/RCLS) is characterized by either the fusion gene FUS-DDIT3 or the less commonly occurring EWSR1-DDIT3 and most cases carry few or no additional cytogenetic changes.
|
25393000 |
2014 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myxoid liposarcoma with cartilaginous differentiation: identification of the same type II TLS-CHOP fusion gene transcript in both lipogenic and chondroid components.
|
18091394 |
2007 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
|
26897615 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking of this pathway by TLS-CHOP may play a mechanistic role in the establishment of myxoid liposarcoma.
|
8125258 |
1994 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The FUS gene is rearranged in the t(12;16)(q13;p11) that characterizes myxoid liposarcoma and in acute myeloid leukemia with t(16;21)(p11;q22), while the ATF-1 gene is rearranged in the t(12;22)(q13;q12) found recurrently in clear cell sarcomas (malignant melanoma of soft parts).
|
11063792 |
2000 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TLS-CHOP fusion is highly sensitive and specific for the entity of classic myxoid/round cell LS.
|
11229517 |
2000 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The detection of fusion genes induced by tumor-specific translocations, such as EWS-FLI1 in Ewing's sarcoma, SYT-SSX in synovial sarcoma, and CHOP-FUS in myxoid liposarcoma, is becoming significant for clinical diagnosis, because these sarcomas are often indistinguishable from other bone and soft-tissue tumors.
|
10982695 |
2000 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we studied a subgroup of sarcomas and leukaemias characterized by the FET (FUS, EWSR1, TAF15) family of fusion oncogenes, including FUS-DDIT3 in myxoid liposarcoma (MLS).
|
26865464 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
|
27270875 |
2016 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present 2 cases of liposarcoma arising in the vulva: a myxoid liposarcoma harboring DDIT3 and FUS rearrangements and a well differentiated liposarcoma/atypical lipomatous tumor harboring MDM2 amplification detected by fluorescence in situ hybridization.
|
25851712 |
2015 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This fusion gene as a hallmark of MLPS is very useful for differential diagnosis from other soft tissue sarcomas, and the associated protein, FUS-DDIT3, performs an important role in the phenotypic selection of targeted multipotent mesenchymal cells during oncogenesis.
|
29181103 |
2017 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
|
29190494 |
2018 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts, namely ML017, ML015 and ML004 differing for the break point of the fusion gene FUS-CHOP, respectively of type I, II and III.
|
24213580 |
2014 |
|
Myxoid/Round Cell Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The myxoid/round cell liposarcoma oncogene FUS-DDIT3 is the result of a translocation derived gene fusion between the splicing factor FUS and DDIT3.
|
15688424 |
2005 |